Goch Aleksander, Banach Maciej, Mikhailidis Dimitri P, Rysz Jacek, Goch Jan Henryk
Department of Cardiology, Medical University of Lodz, Lodz, Poland.
Clin Exp Hypertens. 2009 Feb;31(1):20-30. doi: 10.1080/10641960802409846.
Endothelial dysfunction plays an important role in the pathogenesis of hypertension. Other risk factors of atherosclerosis also affect its development. The aim of the study was to assess nitric oxide metabolites concentration (nitrites and nitrates No(x)) and endothelin (ET-1) in plasma and cyclic 3,5-guanosine monophosphate (cGMP) in 24 h-urine collection in patients with noncomplicated hypertension without risk factors of atherosclerosis and in hypertensive patients with coronary artery disease (CAD). Sixty-eight subjects were included in the study (44 men, 24 women), aged 47 +/- 76 years, allotted into four groups: I - controls (18 clinically healthy subjects); II - 12 subjects with hypertension without risk factors of atherosclerosis; III - 16 subjects with hypertension and risk factors of atherosclerosis; and IV - 22 subjects with hypertension and CAD. Plasma NO(x) concentration was determined using the Greiss method, plasma ET-1 by ELISA, and urine cGMP using the immunoenzymatic method. Plasma NO(x) concentration was 14.00 +/- 6.88 micromol/L in group I, in group II - 18.62 +/- 5.84 micromol, in group III - 9.96 +/- 4.72 micromol/L, and in group IV - 8.78 +/- 3.72 micromol/L. Statistically significant differences were between groups I and III (p < 0.05) and I and IV (p < 0.04) and groups II and III (p < 0.01) and II and IV (p < 0.01). The concentration of cGMP in 24 h urine collection was in group I - 40 +/- 24 pmol/L; in group II - 54 +/- 41 pmol/L; in group III - 38 +/- 32 pmol/L; and in group IV - 42 +/- 36 pmol/L. There were no significant differences between the groups. Plasma ET-1 concentration was 3.86 +/- 0.52 pg/mL in group I, in group II - 4.05 +/- 0.71 pg/mL, in group III - 4.22 +/- 0.79 pg/mL and in group IV - 4.38 +/- 0.75 pg/mL. Statistically significant differences were between group I and III (p < 0.05), I and IV (p < 0.03), and between group II and IV (p < 0.04). Endothelial dysfunction was not found in hypertensive patients without a family history of cardiovascular diseases and without other risk factors of atherosclerosis. Deterioration of endothelial function was observed in patients with hypertension with risk factors of atherosclerosis. It was most pronounced in those with CAD.
内皮功能障碍在高血压发病机制中起重要作用。动脉粥样硬化的其他危险因素也会影响其发展。本研究旨在评估无动脉粥样硬化危险因素的单纯高血压患者以及合并冠心病(CAD)的高血压患者血浆中一氧化氮代谢产物浓度(亚硝酸盐和硝酸盐,即No(x))、内皮素(ET-1)以及24小时尿样中环状3,5-鸟苷单磷酸(cGMP)的水平。68名受试者纳入研究(44名男性,24名女性),年龄47±76岁,分为四组:I组——对照组(18名临床健康受试者);II组——12名无动脉粥样硬化危险因素的高血压患者;III组——16名有动脉粥样硬化危险因素的高血压患者;IV组——22名合并CAD的高血压患者。采用格里斯方法测定血浆No(x)浓度,ELISA法测定血浆ET-1,免疫酶法测定尿cGMP。I组血浆No(x)浓度为14.00±6.88微摩尔/升,II组为18.62±5.84微摩尔,III组为9.96±4.72微摩尔/升,IV组为8.78±3.72微摩尔/升。I组与III组(p<0.05)、I组与IV组(p<0.04)、II组与III组(p<0.01)以及II组与IV组(p<0.01)之间存在统计学显著差异。24小时尿样中cGMP浓度在I组为40±24皮摩尔/升;II组为54±41皮摩尔/升;III组为38±32皮摩尔/升;IV组为42±36皮摩尔/升。各组之间无显著差异。I组血浆ET-1浓度为3.86±0.52皮克/毫升,II组为4.05±0.71皮克/毫升,III组为4.22±0.79皮克/毫升,IV组为4.38±0.75皮克/毫升。I组与III组(p<0.05)、I组与IV组(p<0.03)以及II组与IV组(p<0.04)之间存在统计学显著差异。无心血管疾病家族史且无其他动脉粥样硬化危险因素的高血压患者未发现内皮功能障碍。有动脉粥样硬化危险因素的高血压患者出现内皮功能恶化。在合并CAD的患者中最为明显。